3rd Feb 2006 09:48
Oxford Biomedica PLC03 February 2006 For immediate release 3 FEBRUARY 2006 OXFORD BIOMEDICA ANNOUNCES BOARD APPOINTMENT Oxford, UK: 3 February 2006 - Oxford BioMedica (LSE: OXB), the leading genetherapy company, today announces that, with immediate effect, Dr Mike McDonaldhas been promoted to the Board as an executive director. He will maintain histitle of Chief Medical Officer. His primary responsibilities include theCompany's clinical development activities and regulatory affairs. Mike has over 20 years of experience in clinical drug development and regulatoryleadership. He joined Oxford BioMedica in September 2005 from Seattle Genetics,a US based biotechnology company, where he was Chief Medical Officer. Mikespent nine years with Eli Lilly serving as Worldwide Vice President, ClinicalResearch and Medical Affairs, and was previously at SmithKline Beecham for sevenyears where he was involved in worldwide clinical development, regulatorymanagement and was a member of the pharmaceutical development strategycommittee. From these positions Dr McDonald contributed to the successfulregistration and commercialisation of many important pharmaceuticals. Hereceived his medical degree from Edinburgh University, he is a member of theRoyal College of Physicians in London, holds a Diploma in PharmaceuticalMedicine and is a Fellow of the Faculty of Pharmaceutical Physicians. Commenting on the Board appointment, Professor Alan Kingsman, Chief Executive ofOxford BioMedica, said: "Mike has already made a significant and valuablecontribution to the Company since joining last year and has been instrumental inthe preparations for our planned Phase III trial of TroVax in renal cellcarcinoma. We are delighted to welcome him to the Board." There is no other information to be disclosed under Paragraph 9.6.13 R of theListing Rules. -Ends- For further information, please contact:Oxford BioMedica plc: Professor Alan Kingsman, Chief Executive Tel: +44 (0)1865 783 000City/Financial Enquiries: Lisa Baderoon/ Mark Court/ Mary-Jane Johnson Buchanan Tel: +44 (0)20 7466 5000CommunicationsScientific/Trade Press Enquiries: Katja Stout/ Gemma Bradley Tel: +44 (0)20 7886 8150 Northbank Communications Notes to editors: 1. Oxford BioMedica Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in thedevelopment of novel gene-based therapeutics with a focus on the areas ofoncology and neurotherapy. The Company was established in 1995 as a spin outfrom Oxford University, and is listed on the London Stock Exchange. Oxford BioMedica has core expertise in gene delivery, as well as in-houseclinical, regulatory and manufacturing know-how. In oncology, the pipelineincludes an immunotherapy and a gene therapy in multiple Phase II trials, and apreclinical targeted antibody therapy in collaboration with Wyeth. Inneurotherapy, the Company's lead product is a gene therapy for Parkinson'sdisease, which is expected to enter clinical trials in 2006, and four furtherpreclinical candidates. The Company is underpinned by over 80 patent families,which represent one of the broadest patent estates in the field. The Company has a staff of approximately 70 split between its main facilities inOxford and its wholly owned subsidiary, BioMedica Inc, in San Diego, California.Oxford BioMedica has corporate collaborations with Wyeth, Intervet,Sigma-Aldrich, Viragen, MolMed and Kiadis; and has licensed technology to anumber of companies including Merck & Co, Biogen Idec and Pfizer. Further information is available at www.oxfordbiomedica.co.uk This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Oxford Biomedica